Clinigen Group plc Purchase of shares and PDMR notification (2947H)
March 24 2020 - 2:00AM
UK Regulatory
TIDMCLIN
RNS Number : 2947H
Clinigen Group plc
24 March 2020
24 March 2020
Purchase of shares and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"),
announces that, on 23 March 2020, two directors and one of the
senior management team purchased ordinary shares of GBP0.01p each
in the Group. Shaun Chilton bought 10,000 shares, Nick Keher 6,200
shares and David Bryant 4,763 shares.
Shaun Chilton, Group Chief Executive Officer, said:
"Our share purchases are a strong endorsement of our strategy
and underlie our belief in the Company and its prospects.
"We are the world experts in providing access to medicines
across borders and we are working hard to support Hospital
Pharmacists and Physicians across the US, EU and AAA region to help
their patients in the current Coronavirus situation.
"We are confident of the continuing demand for our Clinical and
Unlicensed Medicines services, and for our portfolio of hospital
oncology and anti-infective medicines."
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
detail.
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283 495
010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260 1000
& Joint Broker
James Black / Freddie Barnfield
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
/ Phillip Marriage Email: clinigen@instinctif.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 22 of the top 25 pharmaceutical companies; interacting
with over 15,000 registered users across over 100 countries,
shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit
www.clinigengroup.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Shaun Chilton
--------------------- ------------------------------------
2 Reason for the notification
-----------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------- ------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
-----------------------------------------------------------
a) Name Clinigen Group plc
--------------------- ------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
-----------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------- ------------------------------------
b) Nature of the Purchase of shares
transaction
--------------------- ------------------------------------
c) Currency GBP
--------------------- ------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------- ------------------- ---------------
415.5p per share 10,000 shares
--------------------- ------------------- ---------------
e) Aggregated 10,000 shares
information 415.5p
- Aggregated GBP41,550
volume
- Price
- Aggregated
total
--------------------- ------------------------------------
f) Date of the 23 March 2020
transaction
--------------------- ------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------- ------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Nick Keher
--------------------- ------------------------------------
2 Reason for the notification
-----------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------- ------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
-----------------------------------------------------------
a) Name Clinigen Group plc
--------------------- ------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
-----------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------- ------------------------------------
b) Nature of the Purchase of shares
transaction
--------------------- ------------------------------------
c) Currency GBP
--------------------- ------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------- ------------------- ---------------
400p per share 6,200 shares
--------------------- ------------------- ---------------
e) Aggregated 6,200 shares
information 400p
- Aggregated GBP24,800
volume
- Price
- Aggregated
total
--------------------- ------------------------------------
f) Date of the 23 March 2020
transaction
--------------------- ------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------- ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAFDDAAXEEAA
(END) Dow Jones Newswires
March 24, 2020 03:00 ET (07:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024